IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4521
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$24M
Christopher A. Bunka
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$LEXX Lexaria Bioscience Corp. | 30 | 22 | 36 | 12 | - | - | -239.0% | -178.7% | 99.5% | -1733.1% | -1737.2% | -100.0% | 0.0% | 34.0x | $24M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Lexaria Bioscience Corp. (LEXX) receives a "Avoid" rating with a composite score of 30.1/100. It ranks #4521 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Christopher A. Bunka
Chief Executive Officer
Labor Force
7
22
36
36
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for LEXX
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for LEXX.
View All RatingsHigh margin volatility — erratic forensic earnings quality
ROE proxy -239.0% (sector -2.5%)
GM 100% vs sector 43%, OM -1733% vs sector 1%
Capital turnover N/A
Rev growth -100%, 11yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Lexaria Bioscience Corp. with an Avoid rating, assigning a composite score of 30.1/100 and 1 out of 5 stars. Ranked #4521 of 7,333 stocks, LEXX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Lexaria Bioscience Corp. registers a weak quality score of just 22/100, indicating significant profitability challenges. The company reports a return on equity of -239.0% (sector avg: -2.5%), gross margins of 99.5% (sector avg: 42.5%), net margins of -1737.2% (sector avg: -0.2%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 36/100, LEXX appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 3.58x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Lexaria Bioscience Corp.'s investment score of 36/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -100.0% vs. a sector average of 5.9% and a return on assets of -178.7% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Lexaria Bioscience Corp. is experiencing notably weak momentum with a score of just 12/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -100.0% year-over-year, while a beta of 1.09 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
LEXX's stability score of 36/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.09 and a debt-to-equity ratio of 34.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
LEXX carries a short interest score of 61/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 34.00x), micro-cap liquidity risk. At $24M market cap (micro-cap), Lexaria Bioscience Corp. offers reasonable institutional liquidity.
Lexaria Bioscience Corp. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4521 of 7,333 overall (38th percentile). Key comparisons include ROE of -239.0% trailing the -2.5% sector median and operating margins of -1733.1% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While LEXX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (12) would have the largest impact on the composite score.
ROE 9538% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 134% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 134451% BELOW SECTOR MEDIAN
AUDIT DATA AS OF NOV 30, 2025 (Q3 FY2025)
We rate Lexaria Bioscience Corp. (LEXX) as Avoid with a composite score of 30.1/100 at a current price of $0.63. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in value (36th percentile) and investment (36th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (12th percentile) and quality (22th percentile) tempers our overall conviction. We assign a No Moat rating (20/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is widening, which provides additional comfort in the durability of the competitive position.
Lexaria Bioscience Corp. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 30.1/100 places it at rank #4521 in our full 7,333-stock universe. At $24M in market capitalization, Lexaria Bioscience Corp. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -100% combined with momentum at the 12th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 100% (+57.0pp vs sector) narrow to operating margins of -1733% (-1734.4pp vs sector) and net margins of -1737.2%, yielding a gross-to-net conversion rate of -1746%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.63, Lexaria Bioscience Corp. is trading at a premium to fundamental value. Our value factor score of 36/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 3.6x, P/S of 30.4x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
The Avoid rating (composite 30.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -100% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -1737.2% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (12th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a High uncertainty rating to Lexaria Bioscience Corp.. Key risk factors include current negative profitability (net margin -1737.2%), below-average price stability (36th percentile), weak quality scores (22th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -1737.2%); below-average price stability (36th percentile); weak quality scores (22th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 36th percentile and quality factor at the 22th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Lexaria Bioscience Corp.'s capital allocation as Poor. Key concerns include low returns on equity (-239.0%), negative profitability, weak asset returns (ROA -178.7%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Lexaria Bioscience Corp. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Lexaria Bioscience Corp. receives a Avoid rating with a composite score of 30.1/100 (rank #4521 of 7,333). Our quantitative framework assigns a No Moat (20/100, trend: widening), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 28/100.
Our analysis does not support a constructive view on Lexaria Bioscience Corp. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Lexaria Bioscience Corp. a meaningful economic moat, scoring 20/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 7.9/20.
The strongest moat sources are margin superiority (7.9/20) and financial resilience (5.8/20). GM 100% vs sector 43%, OM -1733% vs sector 1%. Interest coverage N/A. These pillars form the core of Lexaria Bioscience Corp.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and economic value creation (1.7/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Widening. ROIC has trended upward at ~7.3pp per year, and operating margin trajectory confirms strengthening economics. Lexaria Bioscience Corp.'s competitive position is improving on a fundamental basis. We expect the moat score to drift upward if these trends persist over the next 12–18 months.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, declining revenues (-100%) that pressure the earnings outlook. The margin cascade from 100% gross to -1733% operating to -1737.2% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 22th percentile.
The margin profile shows gross margins of 100%, operating margins of -1733%, net margins of -1737.2%. Return metrics include ROE of -239.0% and ROA of -178.7%. Relative to the Manufacturing sector, gross margins are 57.0 percentage points above the sector median of 43%, and ROE of -239.0% compares to a sector median of -2.5%.
The balance sheet reflects moderate leverage with D/E of 34%, revenue growth of -100%. The sector median D/E is 0%, putting Lexaria Bioscience Corp. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Below-average quality (22th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Above 50MA
37.18%
Net New Highs
+51081
Company Further Examining the Pursuit of the World's First Oral Liraglutide Product KELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms ...
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported quarterly losses of 4 cents per share which beat the analyst consensus estimate of losses of 10 cents by 60%. Quarterly sales came in at $171.1 million, beating the analyst consensus estimate of $167.676 million by 2.04%. The company expects fiscal year 2025 adjusted losses of between 22 cents and 19 cents per share, versus the losses of 22 cents estimate and fiscal year revenues of between $716 million and $722 million, versus the $724.75 estimate. Asana shares dipped 11% to $16.72 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers ClearOne, Inc. (NASDAQ: CLRO) rose 168.4% to $2.4299. ClearOne announced a special one-time cash dividend of 50 cents per share. Regulus Therapeutics Inc. (NASDAQ: RGLS) climbed 74.3% to $2.4050 after the company announced topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The company announced an oversubscribed $100 million private placement of equity. Assure Holdings Corp. (NASDAQ: IONM) gained 49% to $0.4880. Assure Holdings entered into an agreement to sell certain of its assets to MPOWERHealth for up to $4.5 million. Ranpak Holdings Corp. (NASDAQ: PACK) shares gained 40.1% to $6.12 after the company reported better-than-expected fourth-quarter revenue results and issued FY24 guidance. Also, Baird maintained an Outperform rating on the stock and raised its price target from $5 to $7. Singularity Future Technology Ltd. (NASDAQ: SGLY) climbed 37.6% to $4.3321 after gaining over 6% on Monday. Li-Cycle Holdings Corp. (NASDAQ: LICY) gained 27.4% to $0.5111 after the company entered an agreement to issue a senior secured convertible note in an aggregate principal amount of $75 million to an affiliate of Glencore. Nukkleus Inc. (NASDAQ: NUKK) shares rose 22.5% to $1.41 after surging over 43% on Monday. ATRenew Inc. (NYSE: RERE) gained 17.7% to $1.4003 after the company ...
Upgrades For Vintage Wine Estates Inc (NASDAQ:VWE), Canaccord Genuity upgraded the previous rating of Sell to Hold. Vintage Wine Estates earned $0.11 in the second quarter, compared to $0.17 in the year-ago quarter. At the moment, the stock has a 52-week-high of $7.83 and a 52-week-low of $0.81. Vintage Wine Estates closed at $1.06 at the end of the last trading period. DA Davidson upgraded the previous rating for Harley-Davidson Inc (NYSE:HOG) from Neutral to Buy. Harley-Davidson earned $2.04 in the first quarter, compared to $1.45 in the year-ago quarter. At the moment, the stock has a 52-week-high of $51.77 and a 52-week-low of $30.85. Harley-Davidson closed at $36.60 at the end of the last trading period. BTIG upgraded the previous rating for Forestar Group Inc (NYSE:FOR) from Neutral to Buy. For the third quarter, Forestar Group had an EPS of $0.93, compared to year-ago quarter EPS of $0.80. At the moment, the stock has a 52-week-high of $25.99 and a 52-week-low of $10.28. Forestar Group closed at $25.28 at the end of the last trading period. According to B of A Securities, the prior rating for Consolidated Edison Inc (NYSE:ED) was changed from Neutral to Buy. In the first quarter, Consolidated Edison showed an EPS of $1.83, compared to $1.47 from the year-ago quarter. At the moment, the stock has a 52-week-high of $102.19 and a 52-week-low of $78.21. Consolidated Edison closed at $95.89 at the end of the last trading period. According to B of A Securities, the prior rating for Marsh & McLennan Companies Inc (NYSE:MMC) was changed from Underperform to Neutral. In the second quarter, Marsh & McLennan showed an EPS of $2.20, compared to $1.89 from the year-ago quarter. The current stock performance of Marsh & McLennan shows a 52-week-high of $190.92 and a 52-week-low of $148.11. Moreover, at the end of the last trading period, the closing price was at $189.20. Baird upgraded the previous rating for WNS (Holdings) Ltd (NYSE:WNS) from Neutral to Outperform. In the first quarter, WNS (Hldgs) showed an EPS of $1.01, compared to $0.90 from the year-ago quarter. At the moment, the stock has a 52-week-high of $94.96 and a 52-week-low of $67.34. WNS (Hldgs) closed at $68.43 at the end of the last trading period. For Abbott Laboratories (NYSE:ABT), Wolfe Research upgraded the previous rating of Underperform to Peer Perform. For the second quarter, Abbott Laboratories had an EPS of $1.08, compared to year-ago quarter EPS of $1.43. The stock has a 52-week-high of $115.69 and a 52-week-low of $93.29. At the end of the last trading period, Abbott Laboratories closed at $111.83. Piper Sandler upgraded the previous rating for SL Green Realty Corp (NYSE:SLG) from Neutral to Overweight. SL Green Realty earned $1.43 in the second quarter, compared to $1.87 in the year-ago quarter. The stock has a 52-week-high of $51.69 and a 52-week-low of $19.06. At the end of the last trading period, SL Green Realty closed at $33.61. See all analyst ratings upgrades. Downgrades For Sirius XM Holdings Inc (NASDAQ:SIRI), Seaport Global downgraded the previous rating of Neutral to Sell. For the first quarter, Sirius XM Holdings had an EPS of $0.06, compared to year-ago quarter EPS of $0.08. At the moment, the stock has a 52-week-high of $7.95 and a 52-week-low of $3.32. Sirius XM Holdings closed at $7.81 at the end of the last trading period. For The Timken Co (NYSE:TKR), B of A Securities downgraded the previous rating of Buy to Neutral. In the first quarter, Timken showed an EPS of $2.09, compared to $1.61 from the year-ago quarter. The current stock performance of Timken shows a 52-week-high of $95.08 and a 52-week-low of $57.59. Moreover, at the end of the last trading period, the closing price was at $93.07. Wells Fargo downgraded the previous rating for Equinix Inc (NASDAQ:EQIX) from Overweight to Equal-Weight. In the first quarter, Equinix showed an EPS of $8.59, compared to $7.16 from the year-ago quarter. The current stock performance of Equinix shows a 52-week-high of $816.22 and a 52-week-low of $495.11. Moreover, at the end of the last trading period, the closing price was at $810.51. According to Deutsche Bank, the prior rating for Sirius XM Holdings Inc (NASDAQ:SIRI) was changed from Buy to Sell. In the first quarter, Sirius XM Holdings showed an EPS of $0.06, compared to $0.08 from the year-ago quarter. The current stock performance of Sirius XM Holdings shows a 52-week-high of $7.95 and a 52-week-low of $3.32. Moreover, at the end of the last trading period, the closing price was at $7.81. For Blackstone Inc (NYSE:BX), JP Morgan downgraded the previous rating of Overweight to Neutral. In the second quarter, Blackstone showed an EPS of $0.93, compared to $1.49 from the year-ago quarter. At the moment, the stock has a 52-week-high of $110.87 and a 52-week-low of $71.73. Blackstone closed at $107.51 at the end of the last trading period. According to B of ...Full story available on Benzinga.com
Gainers CohBar, Inc. (NASDAQ: CWBR) shares jumped 161% to $4.05 after the company and Morphogenesis announced they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline. HeartCore Enterprises, Inc. (NASDAQ: HTCR) gained 76.6% to $2.26 following better-than-expected first-quarter results. Ocean Biomedical, Inc. (NASDAQ: OCEA) shares climbed 63% to $8.57 after the company announced a patent award for novel cancer immunotherapy treatment, granted for prostate cancer, colon cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma and lung cancer. Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) surged 44% to $1.50 after it was granted U.S. patent #11654157: Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation. Unique Fabricating, Inc. (NYSE: UFAB) climbed 32.8% to $0.2599 after the company announced an accommodation agreement and new forbearance agreement to support a restructuring or sale. Icosavax, Inc. (NASDAQ: ICVX) gained 29.7% to $10.21 after the company announced topline interim Phase 1 results for its bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults. mCloud Technologies Corp. (NASDAQ: MCLD) jumped 27% to $0.4567 after the company announced it has formed a special committee for the purpose of exploring strategic alternatives. Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) gained 22.6% to $9.96. IMAC Holdings, Inc. (NASDAQ: BACK) climbed 21.9% to $0.1702. Theralink signed definitive merger agreement to be acquired by IMAC Holdings. TuSimple Holdings Inc. (NASDAQ: TSP) climbed 21.2% to $2.01. Lexaria Bioscience Corp. (NASDAQ: LEXX) climbed 20.4% to $0.83. Lexaria Bioscience recently announced it completed its HOR-A22-1 study that showed significant enhancement in the oral delivery of the estrogen hormone estradiol. PacWest Bancorp (NASDAQ: PACW) shares gained 20% to $8.23. PacWest Bancorp shares jumped around 20% on Monday after the company announced it entered into a loan purchase and sale agreement with a subsidiary of Kennedy-Wilson Holdings to sell a portfolio of ...
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. ClearOne, Inc. (NASDAQ: CLRO) climbed 66.1% to $2.06 after the company announced a special one-time cash dividend of $1.00 per share of common stock, payable May 31 to shareholders of record on May 22, 2023. Ensysce Biosciences, Inc. (NASDAQ: ENSC) gained 52.8% to $5.26 after the company announced completion of PF614-MPAR-101, a clinical study examining its first pain medication with overdose protection, PF614-MPAR. Mobiquity Technologies, Inc. (NASDAQ: MOBQ) climbed 48.5% to $0.2302 after gaining around 7% on Monday. Novavax, Inc. (NASDAQ: NVAX) shares climbed 46.4% to $10.91 after the company reported mixed Q1 financial results and issued FY23 revenue guidance above estimates. Neuronetics, Inc. (NASDAQ: STIM) gained 37.3% to $3.02 after the company reported better-than-expected Q1 sales results, issued Q2 guidance and raised FY23 total worldwide revenue guidance. Shengfeng Development Limited (NASDAQ: SFWL) rose 26.7% to $5.62. Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) climbed 25.6% to $8.51 following upbeat Q1 results. VirnetX Holding Corporation (NYSE: VHC) surged 25.5% to $0.44 after the company announced a partnership with Samsung. Tivic Health Systems, Inc. (NASDAQ: TIVC) gained 25.4% to $0.1630. Tivic Health, on Monday, launched a B2B portal. Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares rose 22.1% to $10.15 after reporting a profit for the first quarter. Rover Group, Inc. (NASDAQ: ROVR) gained 18.8% to $4.80 following strong quarterly results. Palantir Technologies Inc. (NYSE: PLTR) surged 17.8% to $9.12 after the company reported strong Q1 results and said it expects to remain profitable each quarter through the end of the year. Aris Water Solutions, Inc. (NYSE: ARIS) gained 17.5% to $8.47 following better-than-expected quarterly results. Vivid Seats Inc. (NASDAQ: SEAT) rose 17.1% to $9.24 after the company reported better-than-expected Q1 sales results and raised FY23 revenue guidance above estimates. Maris-Tech Ltd. (NASDAQ: MTEK) gained 17% to $0.9805 after the company announced it entered into an agreement with Art of Logic Australia for $7.5 million of a new product based on the company's Uranus-AI product. ERYTECH Pharma S.A. (NASDAQ: ERYP) rose 17% to $1.03 after the company provided a business and financial update for Q1. NeoGenomics, Inc. (NASDAQ: NEO) ...